No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study

SIMPLE SUMMARY: Neuroblastoma RAS Viral Oncogen Homolog (NRAS) mutant melanoma is usually considered more aggressive and more responsive to checkpoint inhibitor immunotherapy (CII) than NRAS wildtype. We retrospectively recruited 331 metastatic melanoma patients treated with CII as first line: 162 N...

Descripción completa

Detalles Bibliográficos
Autores principales: Guida, Michele, Bartolomeo, Nicola, Quaglino, Pietro, Madonna, Gabriele, Pigozzo, Jacopo, Di Giacomo, Anna M., Minisini, Alessandro M., Tucci, Marco, Spagnolo, Francesco, Occelli, Marcella, Ridolfi, Laura, Queirolo, Paola, De Risi, Ivana, Quaresmini, Davide, Gambale, Elisabetta, Chiaron Sileni, Vanna, Ascierto, Paolo A., Stigliano, Lucia, Strippoli, Sabino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865301/
https://www.ncbi.nlm.nih.gov/pubmed/33530579
http://dx.doi.org/10.3390/cancers13030475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865301/
https://www.ncbi.nlm.nih.gov/pubmed/33530579
http://dx.doi.org/10.3390/cancers13030475

Ejemplares similares